Jump to content

Relacorilant

From Wikipedia, the free encyclopedia

Relacorilant
Clinical data
Trade namesLifyorli
Other namesCORT-125134
AHFS/Drugs.comlifyorli
License data
Routes of
administration		By mouth
Drug classAntiglucocorticoid
ATC code
  • None
Legal status
Legal status
Identifiers
  • [(4aR)-1-(4-Fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC27H22F4N6O3S
Molar mass586.57 g·mol−1
3D model (JSmol)
  • CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
  • InChI=1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1
  • Key:WANIDIGFXJFFEL-SANMLTNESA-N

Relacorilant, sold under the brand name Lifyorli, is an anti-cancer medication used for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.[1] Relacorilant is a glucocorticoid receptor antagonist.[1]

The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.[2]

Relacorilant was approved for medical use in the United States in March 2026.[2][3]

Medical uses

[edit]

Relacorilant is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.[1]

Adverse effects

[edit]

The US prescribing information includes a contraindication for people who require corticosteroids for a lifesaving indication as well as warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity.[2] The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.[2]

History

[edit]

Efficacy was evaluated in ROSELLA (NCT05257408), a multicenter, open-label, trial in 381 participants with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.[2] Participants were permitted to receive up to three prior lines of systemic therapy and prior bevacizumab was required.[2] The trial excluded participants who required chronic or frequent use of glucocorticoids.[2] Participants were randomized (1:1) to receive relacorilant in combination with nab-paclitaxel or nab-paclitaxel alone.[2]

References

[edit]
  1. ^ a b c d "Lifyorli- relacorilant kit". DailyMed. 26 March 2026. Retrieved 1 April 2026.
  2. ^ a b c d e f g h "FDA approves relacorilant with nab-paclitaxel for platinum-resistant". U.S. Food and Drug Administration (FDA). 25 March 2026. Retrieved 5 April 2026. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ Kansteiner F (25 March 2026). "Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer". Fierce Pharma. Retrieved 26 March 2026.
[edit]
  • Clinical trial number NCT05257408 for "Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer" at ClinicalTrials.gov


Stub icon

This hormonal preparation article is a stub. You can help Wikipedia by adding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Relacorilant&oldid=1347735625"